RCAMU
TCRR

Rothschild & Co Asset Management US’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Rothschild & Co Asset Management US’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-348,395
Closed -$2.96M – 283
2021
Q3 		$2.96M Sell
348,395
-341,879
-50% -$4.83M 0.04% 240
2021
Q2 		$11.3M Buy
690,274
+131,563
+24% +$2.66M 0.13% 176
2021
Q1 		$12.3M Sell
558,711
-130,338
-19% -$3.55M 0.15% 175
2020
Q4 		$21.3M Buy
+689,049
New +$17.4M 0.27% 128

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Rothschild & Co Asset Management US's TCRR Position: Q4 2021 in Review

Rothschild & Co Asset Management US sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q4 2021, closing a stake of 348,395 shares — an estimated $2.96M sold.

Rothschild & Co Asset Management US first reported a position in TCRR in Q4 2020 and held it in 4 quarters. The position peaked at $21.3M in Q4 2020. 122 funds tracked by Wall St. Rank hold TCRR as of Q4 2021.

  • Rothschild & Co Asset Management US reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Rothschild & Co Asset Management US sold 348,395 TCR2 Therapeutics Inc. Common Stock shares in Q4 2021, an estimated $2.96M.
  • Rothschild & Co Asset Management US first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2020 and held it in 4 quarters.
  • Rothschild & Co Asset Management US's TCR2 Therapeutics Inc. Common Stock position peaked at $21.3M in Q4 2020.
  • 122 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q4 2021.

Based on Rothschild & Co Asset Management US's 13F filing for Q4 2021, filed 11 Feb 2022.